Comments
Nasdaq-listed Vivus Inc today entered into a settlement agreement with Dr Reddy’s Laboratories to resolve a long-pending patent litigation related to weight management capsules Qsymia.
According to a statement issued by the US-based drug maker, the litigation, pending since 2015, resulted from the submission of an abbreviated new drug application (Anda) by Dr Reddy’s seeking approval to market generic versions of Qsymia.
The settlement permits the drugmaker to begin selling a generic version of Qsymia from June 2025, or earlier under certain circumstances.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.